EUCTR2012-000854-73-GB进行中（未招募）不适用
A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS - Study to Test TCN-032 as a Treatment for Influenza.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects will be considered eligible if they satisfy all of the following inclusion criteria:
- •1. Age 18 to 45 years, inclusive.
- •2. In good health with no history of major medical conditions from medical history, physical examination, and routine laboratory tests as determined by the Investigator by a screening evaluation no greater than 45 days prior to inoculum.
- •3. Body weight between 50 and 100 kg, inclusive (body mass index [BMI] >18 kg/m2 to <33 kg/m2).
- •4. Female subjects must not be pregnant or nursing and must either be of non-childbearing potential (e.g. surgically sterile) or agree to use reliable contraceptive practices as in Table 2 (2 methods must be used) should they be heterosexually active. The provision of this history does NOT replace the requirement to perform, and obtain negative results in pregnancy tests and subjects must refrain from becoming pregnant until 4 months after IMP dosing. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female condoms and male condoms should not be used together as friction between the two can result in either product failing. Postmenopausal: Female subjects who have been amenorrheic for at least 2 years and have a serum follicle-stimulating hormone (FSH) level within the laboratory’s reference range for postmenopausal females.
- •5. For non-sterilised male subjects who are heterosexually active, agreement to use 2 effective forms of birth control from admission into quarantine, and refrain from fathering a child at least until 4 months after the IMP dosing. Female condoms and male condoms should not be used together as friction between the two can result in either product failing. If a male subject has had a vasectomy (with a negative sperm post-vasectomy semen analysis) 6 months or greater before the Screening Visit, one additional contraception method is required until 4 months after dose of IMP.
- •6. Willingness to provide written consent for participation after reading the Subject Information Sheet and Consent Form and after having adequate opportunity to discuss the study with an Investigator. Comprehension of the study requirements; availability for the required study period, ability to attend scheduled study visits, and willingness to participate in the quarantine stay.
- •7. Serosusceptible (HAI titre <10) to the challenge virus at all visits prior to admission into quarantine.
- •8. Have not been vaccinated for influenza virus since 2006 (as determined in the medical history) or had a known influenza-like illness in the current season, defined as in the last 12 months prior to screening.
- •9. Should have a negative cotinine test on Day –2. However if a subject has a positive test on Day –2, then a repeat test on Day –1 or Day 0 must be negative.
- •10. Non smoker or current smoker willing/able to desist for the quarantine phase of the study or anyone who has a cumulative smoking history of = 5 pack years.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 64
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Presence of significant acute or chronic, uncontrolled medical or psychiatric illness
- •2. History of autoimmune disease
- •3. History of adulthood asthma/chronic lung condition
- •4. History of recurrent lower respiratory tract infection or lower respiratory tract infection within 3 months of study
- •5. Positive for HIV, HBV or HCV
- •6. Subject is diabetic
- •7. Anatomic or neurologic abnormality impairing gag reflex
- •8. History of frequent epistaxis
- •9. Known IgA deficiency, immotile cilia syndrome or Kartageners syndrome
- •10. Nasal or sinus surgery within 6 months of study
- •11. Recent and/or recurrent history of autonomic dysfunction
- •12. Abnormal laboratory test deemed clinically significant
- •13. Abnormal ECG or abnormal spirometry deemed clinically relevant
- •14. Acute medical condition or significant past medical history of hepatic, renal, cardiovascular, pulmonary, gastrointestinal, hematological, locomotor, immunologic, ophthalmologic, metabolic, endocrine, or other diseases
- •15. Major surgery within 3 months of study
- •16. Evidence of drug abuse or positive urine Class A drug or alcohol screen
- •17. Venous access deemed inadequate
- •18. Subjects symptomatic with hay fever on admission into the unit for quarantine session or prior to viral inoculation will be excluded.
- •19. History of significant adverse reactions or allergies
- •20. History of allergy or intolerance to oseltamivir or zanamivir.
- •21. Health care workers
- •22. Presence of household member or close contact (for 2 weeks after discharge) who is at risk of contracting influenza
- •23. Intending to travel within the next 3 months
- •24. Employed or immediate relatives of those employed at RVL or Sponsor.
- •25. Receipt of blood or blood products or loss of >450 mL of blood within 3 months of study
- •26. Acute use of medication for rhinitis or nasal congestion within 1 week of study
- •27. Use of prescription drugs, herbal supplements, within 4 weeks of study at the discretion of the Investigator in conjunction with TCN
- •28. Chronic use of any medication for rhinitis/nasal congestion or chronic nasopharyngeal complaint
- •29. Receipt of any investigational drug within 3 months of study or prior participation in a clinical trial of influenza vaccine, experimental influenza viral challenge or other respiratory virus challenge within 1year prior study
- •30. Receipt of antiviral drugs within 1 month of study
- •31. Receipt of systemic glucocorticoids, immunoglobulins (Igs), other cytotoxic/immunosuppressive drugs, or systemic chemotherapy agent
- •32. Previous treatment with monoclonal antibodies
- •33. Presence of febrile illness/symptoms of viral respiratory infection within 2 weeks prior study
- •34. Physical examination or screening investigations which lead the Investigator(s) to consider the subject unfit for the study
- •35. Subjects, who in the opinion of their General Practitioner or the Chief Investigator or designee, should not participate in the study
研究者
相似试验
招募中
3 期
“A Phase II, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of mesenchymal cells (MSV-ALLO®) in the treatment of lupus nephritis”Lupus Nephritis2024-514750-67-00Hospital Universitario Rio Hortega20
进行中（未招募）
1 期
A Randomized Phase II Study of GDC-0068, an Inhibitor to Akt, in Combination with Fluoropyrimidine Plus Oxaliplatin Chemotherapy (mFOLFOX6) in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.Inoperable locally advanced or metastatic or recurrent gastric or gastroesophageal adenocarcinoma.MedDRA version: 19.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864EUCTR2012-002080-10-DEGenentech, Inc.153
进行中（未招募）
1 期
A Randomized Phase II Study of GDC-0068, an Inhibitor to Akt, in Combination with Fluoropyrimidine Plus Oxaliplatin Chemotherapy (mFOLFOX6) in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.Inoperable locally advanced or metastatic or recurrent gastric or gastroesophageal adenocarcinoma.MedDRA version: 16.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864EUCTR2012-002080-10-ESGenentech, Inc.153
进行中（未招募）
不适用
A Randomized Phase II Study of GDC-0068, an Inhibitor to Akt, in Combination with Fluoropyrimidine Plus Oxaliplatin Chemotherapy (mFOLFOX6) in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.Inoperable locally advanced or metastatic or recurrent gastric or gastroesophageal adenocarcinoma.MedDRA version: 14.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864EUCTR2012-002080-10-GBGenentech, Inc.120
进行中（未招募）
1 期
A Randomized Phase II Study of GDC-0068, an Inhibitor to Akt, in Combination with Fluoropyrimidine Plus Oxaliplatin Chemotherapy (mFOLFOX6) in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.Inoperable locally advanced or metastatic or recurrent gastric or gastroesophageal adenocarcinoma.MedDRA version: 16.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864EUCTR2012-002080-10-ITGenentech, Inc.153